晚期非小细胞肺癌外周血CTC与肿瘤组织EGFR表达的相关性

发布时间：2018-04-12 22:12

本文选题：非小细胞肺癌 + 循环肿瘤细胞　；参考：《中国现代医学杂志》2017年29期

【摘要】：目的探讨晚期非小细胞肺癌(NSCLC)外周血循环肿瘤细胞(CTC)与肿瘤组织表皮生长因子受体(EGFR)表达的一致性。方法利用流式细胞术及免疫组织化学染色配对检测66例NSCLC患者外周血CTC和肿瘤组织EGFR的表达水平。给予EGFR酪氨酸激酶抑制剂治疗1个月后进行疗效评价。比较CTC与肿瘤组织EGFR表达的一致性,并分析其与患者临床因素、疗效及预后的相关性。结果外周血CTC与肿瘤组织EGFR表达一致率为69.7%。CTC与肿瘤组织EGFR的表达在不同组织学类型间比较,差异有统计学意义(P0.05),在不同性别、年龄、分期、体力活动状态评分方面比较,差异无统计学意义(P0.05)。EGFR高表达组疾病控制率高于低表达组(CTC:87.5%vs 35.3%;肿瘤组织:72.7%vs 36.4%)(P0.05)。生存分析结果显示,EGFR高表达组有更长的无进展生存期(CTC:8个月vs 2个月;肿瘤组织:6个月vs 2个月)和总生存期(CTC:20个月vs 13个月;肿瘤组织:16个月vs 14个月)(P0.05)。结论晚期NSCLC患者外周血CTC和肿瘤组织EGFR表达的一致性好,两者对酪氨酸激酶抑制剂治疗的疗效及预后具有一定的预测价值。外周血CTC作为肿瘤组织的替代检测标本是可行的。
[Abstract]:Objective to investigate the expression of circulating tumor cells (CTCC) in peripheral blood of advanced non-small cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR) in tumor tissues.Methods flow cytometry and immunohistochemical staining were used to detect the expression of CTC and EGFR in peripheral blood and tumor tissues of 66 patients with NSCLC.The efficacy of EGFR tyrosine kinase inhibitor was evaluated 1 month later.To compare the consistency of EGFR expression between CTC and tumor tissue, and to analyze its correlation with clinical factors, curative effect and prognosis.Results the coincident rate of EGFR expression between peripheral blood CTC and tumor tissue was compared between 69.7%.CTC and tumor tissue EGFR in different histological types, the difference was statistically significant (P 0.05), and the difference was significant in sex, age, stage, physical activity state score.The disease control rate of high expression group was higher than that of low expression group, and that of tumor tissue was 72.7% vs 36.4%.Survival analysis showed that there were longer progressive survival time (CTC): 8 months vs 2 months; tumor tissue: 6 months vs 2 months; total survival time: 20 months vs 13 months; tumor tissue: 16 months vs 14 months;Conclusion there is good consistency between peripheral blood CTC and tumor EGFR expression in advanced NSCLC patients. Both of them can predict the therapeutic effect and prognosis of tyrosine kinase inhibitor therapy.It is feasible to use peripheral blood CTC as a substitute for detection of tumor tissue.
【作者单位】：昆明医科大学第三附属医院干部医疗科;昆明医科大学第三附属医院病理科;昆明医科大学第三附属医院肿瘤研究所;
【基金】：云南省科技厅应用基础研究面上项目(No:2012FB164) 云南省教育厅重点项目(No:2013Z113)
【分类号】：R734.2

【相似文献】